Want to see SE:MODTX full AI Analyst Report?

Modus Therapeutics Holding AB (MODTX) Price & Analysis

0 Followers

MODTX Stock Chart & Stats

kr0.30

-kr0.02(-1.23%)

At close: Mar 06 4:00 PM EST

kr0.30

-kr0.02(-1.23%)

Day’s Range― - ―

52-Week Rangekr0.21 - kr5.00

Previous CloseN/A

Volume636.00

Average Volume (3M)841.43K

Market Cap

kr41.48M

Enterprise Valuekr29.19

Total Cash (Recent Filing)kr6.93M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta1.45

Next Earnings

Aug 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.15

Shares Outstanding121,628,494

10 Day Avg. Volume409,277

30 Day Avg. Volume841,432

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)2.10

Price to Sales (P/S)0.00

P/FCF Ratio-1.05

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.14

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical-stage Focus On Sickle Cell DiseaseA concentrated clinical focus on sickle cell disease gives Modus a clear strategic niche in a high unmet-need therapeutic area. This specialization supports durable scientific expertise, targeted R&D spend, and potential high long-term commercial value if clinical candidates advance successfully.

Low Reported Financial LeverageZero reported debt provides structural financial flexibility for a development-stage biotech. Low leverage reduces fixed financing costs and interest risk, improving ability to negotiate equity or partnership deals and preserving optionality when funding clinical milestones over the medium term.

Very Lean Operating FootprintAn extremely small headcount implies low fixed overhead and the ability to outsource development work, which can extend runway per financing round. For a pre-revenue biotech, a lean structure supports capital efficiency and focus on core clinical activities over multiple months.

Bears Say

Pre-revenue With Persistent LossesAbsent any revenue across multiple years, Modus cannot self-fund operations; persistent operating losses mean the company depends on external capital to progress trials. This structural revenue gap increases execution risk and limits long-term sustainability without successful commercialization or partnerships.

Worsening Cash Burn TrajectoryRising negative free cash flow indicates shrinking runway and higher near-term financing needs. Structurally increasing burn pressures capital planning, can force dilutive raises or delay programs, and constrains the company's ability to self-finance clinical milestones over the next 2–6 months.

Equity Volatility And Financing DependenceA history of equity volatility and recapitalization risk signals recurring reliance on external funding. Structurally this raises likelihood of dilution, potential shifts in ownership or strategy after financings, and increased governance and execution risk for long-term program continuity.

MODTX FAQ

What was Modus Therapeutics Holding AB’s price range in the past 12 months?

Modus Therapeutics Holding AB lowest stock price was kr0.21 and its highest was kr5.00 in the past 12 months.

What is Modus Therapeutics Holding AB’s market cap?

Modus Therapeutics Holding AB’s market cap is kr41.48M.

When is Modus Therapeutics Holding AB’s upcoming earnings report date?

Modus Therapeutics Holding AB’s upcoming earnings report date is Aug 26, 2026 which is in 24 days.

How were Modus Therapeutics Holding AB’s earnings last quarter?

Modus Therapeutics Holding AB released its earnings results on May 26, 2026. The company reported -kr0.027 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.027.

Is Modus Therapeutics Holding AB overvalued?

According to Wall Street analysts Modus Therapeutics Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Modus Therapeutics Holding AB pay dividends?

Modus Therapeutics Holding AB does not currently pay dividends.

What is Modus Therapeutics Holding AB’s EPS estimate?

Modus Therapeutics Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Modus Therapeutics Holding AB have?

Modus Therapeutics Holding AB has 121,628,494 shares outstanding.

What happened to Modus Therapeutics Holding AB’s price movement after its last earnings report?

Modus Therapeutics Holding AB reported an EPS of -kr0.027 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8.065%.

Which hedge fund is a major shareholder of Modus Therapeutics Holding AB?

Currently, no hedge funds are holding shares in SE:MODTX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Modus Therapeutics Holding AB

Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation. Modus Therapeutics Holding AB (publ) was founded in 2011 and is headquartered in Stockholm, Sweden.